Orchestra BioMed
Business Services · Pennsylvania, United States · 56 Employees
View Company Info for Free
About
Headquarters
150 Union Square Dr, New Hope, Pennsylvania, 18...Phone Number
(215) 862-5797Website
www.orchestrabiomed.comRevenue
<$5 MillionStock Symbol
OBIOIndustry
Most Recent Scoops
Project
Orchestra BioMed is currently enrolling patients in the BackBeat (AVIM) trial, a 500-patient randomized study targeting completion in 2025. The therapy has shown consistent double-digit reductions in ambulatory systolic blood pressure, with data showing durability up to four years.
Partnership
Orchestra BioMed has established strategic partnerships with Medtronic and Terumo for product development and commercialization in the MedTech space. The company focuses on driving product development through pivotal clinical evidence while leveraging partners' commercial organizations for product commercialization.
Highlights
$205M
Total Funding Amount
$110M
Most Recent Funding Amount
4
Number of Funding Rounds
Who is Orchestra BioMed
Orchestra BioMed is a therapeutic device company focused on developing therapeutic solutions for established treatment paradigms. The company is headquartered in New Hope, Pennsylvania.Explore more
Orchestra BioMed Org Chart
Is Orchestra BioMed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Orchestra BioMed has recently received funding, and reach out quickly before it becomes old news!
Check out if Orchestra BioMed is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Orchestra BioMed, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Orchestra BioMed had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Orchestra BioMed
Product Launch: Get notified when Orchestra BioMed launches new products
Funding: Get notified immidiatlly once Orchestra BioMed has new funding data
Earning: See what the market has to say on Orchestra BioMed recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Orchestra BioMed
Compare insights from companies similar to Orchestra BioMed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Orchestra BioMed
<$5M
56
Orchestra BioMed financials insights
Gather financial insights about Orchestra BioMed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Orchestra BioMed Employee Growth Rate
View Orchestra BioMed’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Orchestra BioMed Tech Stack
A closer look at the technologies used by Orchestra BioMed
Most Recent Scoops
Project
Orchestra BioMed is currently enrolling patients in the BackBeat (AVIM) trial, a 500-patient randomized study targeting completion in 2025. The therapy has shown consistent double-digit reductions in ambulatory systolic blood pressure, with data showing durability up to four years.
Search, Medical Research, Clinical Operations, Healthcare Technology, Operations
Partnership
Orchestra BioMed has established strategic partnerships with Medtronic and Terumo for product development and commercialization in the MedTech space. The company focuses on driving product development through pivotal clinical evidence while leveraging partners' commercial organizations for product commercialization.
Partnership, Product Development, Product Management, Search, Medical Research
Project
Orchestra BioMed is developing two flagship programs: AVIM Therapy, a hypertension treatment integrated into standard dual-chamber pacemakers partnered with Medtronic, and Virtue, a novel sirolimus-based drug-eluting balloon for coronary and peripheral artery disease partnered with Terumo.
Product Development, Product Management, Search, Medical Research, Healthcare Technology
Project
will receive significant revenue shares from their partnerships, including $500 to $1,600 on every AVIM-enabled pacemaker Medtronic sells and up to a 15% net sales royalty from Terumo for the Virtue product.
Partnership, Business Finance, Finance, Operations, Revenue Operations
Project
Business Development, Search, Medical Research, Healthcare Technology
Orchestra BioMed News & Media
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY from December 3-5, 2024.Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2024 financial results and provided a business update.Orchestra BioMed to Participate in Jefferies London Healthcare Conference
NEW HOPE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies London Healthcare Conference being held in London, UK from November 19-21, 2024.Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update.
Read more news
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Orchestra BioMed
Sign Up for FreeTo access detailed company insights
Orchestra BioMed is a therapeutic device company focused on developing therapeutic solutions for established treatment paradigms. The company is headquartered in New Hope, Pennsylvania.... Read More
